Evidence map›Paper›PMID 32708578›Full record

ReviewAntioxidants (Basel, Switzerland)2020

The Role of Glutathione in Protecting against the Severe Inflammatory Response Triggered by COVID-19.

Francesca Silvagno, Annamaria Vernone, Gian Piero Pescarmona

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Antioxidants (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06437210 (Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome), which is not on this map. Cited by 125 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 3 pooled it
23.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06437210 nacompletednot on this mapstarted 2022, after this paper: background citation

Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome

TypeinterventionalSponsorCatalysis SLRan2022 to 2024Enrolled200ConditionsPost-COVID-19 Syndrome, COVID-19, Dyspnea, FatigueArmsViusid Oral Solution, Placebo
3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 3 syntheses or guidelines pooled it, 254 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Trial
  7. Trial
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Involvement of oxidative stress in post-acute sequelae of COVID-19: clinical implications.Redox report : communications in free radical research · 2025
    Article
  19. Review
  20. Article

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Francesca SilvagnoDepartment of Oncology, University of Torino, Via Santena 5 bis, 10126 Torino, Italy.ORCID 0000-0002-8800-9135
Annamaria VernoneDepartment of Oncology, University of Torino, Via Santena 5 bis, 10126 Torino, Italy.
Gian Piero PescarmonaDepartment of Oncology, University of Torino, Via Santena 5 bis, 10126 Torino, Italy.
University of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The novel COVID-19 pandemic is affecting the world's population differently: mostly in the presence of conditions such as aging, diabetes and hypertension the virus triggers a lethal cytokine storm and patients die from acute respiratory distress syndrome, whereas in many cases the disease has a mild or even asymptomatic progression. A common denominator in all conditions associated with COVID-19 appears to be the impaired redox homeostasis responsible for reactive oxygen species (ROS) accumulation; therefore, levels of glutathione (GSH), the key anti-oxidant guardian in all tissues, could be critical in extinguishing the exacerbated inflammation that triggers organ failure in COVID-19. The present review provides a biochemical investigation of the mechanisms leading to deadly inflammation in severe COVID-19, counterbalanced by GSH. The pathways competing for GSH are described to illustrate the events concurring to cause a depletion of endogenous GSH stocks. Drawing on evidence from literature that demonstrates the reduced levels of GSH in the main conditions clinically associated with severe disease, we highlight the relevance of restoring GSH levels in the attempt to protect the most vulnerable subjects from severe symptoms of COVID-19. Finally, we discuss the current data about the feasibility of increasing GSH levels, which could be used to prevent and subdue the disease.

Indexed as

angiotensin-converting enzyme 2 (ACE2)angiotensin-converting enzyme (ACE)chloroquineglutathioneglycineinflammationN-acetylcysteineparacetamolROSSARS-CoV-2

Identifiers

PMID32708578
PMCPMC7402141
OpenAlexW3042922222

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.